News Releases

RNS Number : 3554Y MaxCyte, Inc. 02 January 2024   MaxCyte, Inc.   (" MaxCyte " or the "Company")   Total Voting Rights   ROCKVILLE, MD , January 2 ,   2024   -   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT),  a leading, cell-engineering focused company providing enabling platform technologies to
Jan 02, 2024
RNS Number : 3253Y MaxCyte, Inc. 02 January 2024             MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director   ROCKVILLE, MD , January 2, 2024   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing
Jan 02, 2024
RNS Number : 1118Y MaxCyte, Inc. 29 December 2023     MaxCyte, Inc. (" MaxCyte " or the "Company")   Exercise of options and PDMR dealing   ROCKVILLE, MD , December 29, 2023 :   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
Dec 29, 2023
RNS Number : 4671W MaxCyte, Inc. 12 December 2023           THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018     MaxCyte Announces CEO
Dec 12, 2023
RNS Number : 0411W MaxCyte, Inc. 07 December 2023     MaxCyte, Inc. (" MaxCyte " or the "Company")   Exercise of options and PDMR dealing   ROCKVILLE, MD , December 7, 2023 :   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
Dec 07, 2023
RNS Number : 4853V MaxCyte, Inc. 04 December 2023     MaxCyte, Inc. (" MaxCyte " or the "Company")   Exercise of options and PDMR dealing   ROCKVILLE, MD , December 4, 2023 :   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
Dec 04, 2023
ROCKVILLE, Maryland - 1 December 2023: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that pursuant to its block admission facility, since 31 October 2023 it has issued 133,442 of common stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options.
Dec 01, 2023
ROCKVILLE, MD, November 30, 2023: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 27 November 2023, as per a filing lodged with the U.S. Securities and Exchange Commission, John Johnston, a Non-Executive Director of the Company, exercised options over 5,000 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate.
Nov 30, 2023